Kindr Research · Open dataset · CC-BY 4.0

The NAMS Position Statement adoption scorecard

Adoption of the 2022 NAMS Position Statement on Hormone Therapy across U.S. medical specialties, insurance formularies, and residency curricula.

Key findings

• Data compiled from peer-reviewed literature, CDC HCUP, NHANES, SWAN, and Kindr Health de-identified clinical operations data.
• Findings are directional; each stat carries a confidence interval documented in the methodology section.
• This dataset is released under Creative Commons Attribution 4.0 (CC-BY 4.0). Journalists and researchers are free to cite with attribution.
• Kindr Health is a physician-supervised menopause telehealth platform operating in all 50 U.S. states.

Methodology

Kindr Research assembles this dataset from three sources: (1) peer-reviewed literature identified via PubMed and Cochrane, (2) de-identified aggregate signals from Kindr Health clinical operations, and (3) publicly available datasets (CDC, NHANES, SWAN, HCUP, CMS). Confidence intervals reflect underlying study heterogeneity. Ranges are reported at 95% CI where source data permits. This report was reviewed by the Kindr Health Clinical Team prior to publication. It is not intended as medical advice; consult a licensed clinician for individual guidance.

Sources

1. North American Menopause Society (NAMS) 2022 Position Statement on Hormone Therapy
2. ACOG — Committee Opinion on Hormone Therapy
3. Endocrine Society clinical practice guidelines
4. CDC HCUP — Healthcare Cost and Utilization Project
5. SWAN — Study of Women's Health Across the Nation

More Kindr Research: Lifespan Manual · Menopause Data Hub · All research.